Adenosine Deaminase Inhibition for Immunosuppression (Cont.)

Publisher Website
Google Scholar
Abstract
To the Editor: Lum and her co-workers1 have recently reported prolonged survival of skin allografts in mice receiving the adenosine deaminase (ADA) inhibitor erythro-9(2-hydroxy-3-nonyl)-adenine hydrochloride (EHNA). We have been conducting studies on the pharmacologic properties of the considerably more potent adenosine deaminase inhibitor 2′-deoxycoformycin (2′-dCF)2 , 3; the dissociation constant (KI) of the EI complex formed between the latter compound and human red-cell ADA is 2.5 X 10-12 M, as compared with a KI of 1.6 X 10-9 M for EHNA and ADA.4 We should like to report recent studies on the immunosuppressive activity of 2′-dCF with . . .